1 / 17

Treatment of hypertensive patients with heart failure

Treatment of hypertensive patients with heart failure. Jamil Mayet Department of Cardiology and The Peart-Rose Clinic St Mary’s Hospital, NHLI Imperial College, London, UK. Age-adjusted risk of congestive heart failure by hypertensive status. <140/90 >160/90. Kannel WB. Framingham.

jed
Download Presentation

Treatment of hypertensive patients with heart failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Treatment of hypertensive patients with heart failure Jamil Mayet Department of Cardiology and The Peart-Rose Clinic St Mary’s Hospital, NHLI Imperial College, London, UK

  2. Age-adjusted risk of congestive heart failure by hypertensive status <140/90 >160/90 Kannel WB. Framingham

  3. The progression from hypertension to congestive heart failure • 5143 subjects in Framingham study • 392 new cases of clinical CCF after mean follow up of 20 years • In 91% hypertension antedated CCF • MI present in 52% of hypertensive men and 34% of hypertensive women with CCF • Median survival after CCF diagnosis in ht 1.37 years in men and 2.48 in women Levy et al. JAMA 1996;275:1557-62

  4. Age-adjusted BP parameters and CHF risk Hazard Ratio 120-139 140-159 70-79 80-89 54-67 <120 >159 <70 >89 <54 >67 Chae et al. JAMA1999;281:634-9

  5. Treatments that improve CCF and lower BP • Non-pharmacological (salt restriction, exercise) • ACE inhibitors (SOLVD, CONSENSUS) • Beta blockers (CIBIS 2, MERIT-HF) • Diuretics

  6. Age-adjusted BP parameters and CHF risk Hazard Ratio 120-139 140-159 70-79 80-89 54-67 <120 >159 <70 >89 <54 >67 Chae et al. JAMA199;281:634-9

  7. Arterial stiffening in hypertension • Increased PW velocity with early wave reflection • Increased central systolic pressure and lower diastolic pressure • Discrepancy between central and peripheral pressures lessened • Therefore peripheral BP underestimates central effects

  8. Reducing arterial stiffness as a therapeutic goal • Later wave reflection reduces peak central pressure which is caused by summation of systolic wave and reflected wave • In periphery peak pressure is not a summation wave and so there is less of a decrease • Reducing stiffness causes preferential decrease in central compared with peripheral pressures

  9. Non-pharmacological approaches to reducing arterial stiffness • Increased arterial stiffness in obese subjects with improvement following weight reduction • Moderate aerobic exercise increases arterial compliance • Subjects with high salt intake have better arterial distensibility than those with low intake. • Improvement following salt restriction

  10. Stiffness LV Outcome impact regression data ?+ + No a -blockers +++ +++ No ACE-inhibitors + + Yes b -blockers ++ ?? No b -blockers ‘extra’ +++ ++ Yes ++ Ca antagonists + +/++ Yes + thiazides Relation between vascular and LV impacts of antihypertensives

  11. Diastolic heart failure • Symptoms/signs of heart failure with normal or mildly impaired LV systolic function • Prevalence depends on clinical definition of heart failure • May be up to 30% of cases with heart failure • Diastolic dysfunction in hypertensives is very common, particularly in those with LVH

  12. Pathophysiology of diastolic dysfunction • Impaired relaxation • Energy dependent and sensitive to ischaemia • Coronary artery disease • Microvascular ischaemia (arteriolar rarefaction, arteriole wall thickening, perivascular fibrosis, endothelial dysfunction, relative myocyte hypertrophy) • Decreased compliance • Increase in myocardial collagen

  13. Treatment of diastolic dysfunction • Treat underlying cause eg coronary intervention • Most patients are elderly and hypertensive +/- LVH • Beta blockers may improve filling by reducing heart rate and prolonging diastole; also may reduce myocardial O2 demand and regress LVH • Ca antagonists, particularly rate limiting, may have similar effects • BUT VERY LITTLE FUNCTIONAL DATA

  14. Treatment of diastolic dysfunction • Beta blockers and Ca antagonists unlikely to be effective when restrictive physiology with raised LA pressure • Drugs that reduce fibrosis and reduce LA pressure likely to be effective • ACEI, AII antagonists, spironolactone, diuretics • BUT VERY LITTLE FUNCTIONAL DATA

  15. Treatment of diastolic dysfunction • Echo guided strategy • Impaired relaxation • Verapamil • Beta-blockers • Restriction with increased LA pressure • ACEI • AII blockers • Diuretics (spironolactone)

More Related